Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The industry is experiencing a clear turning point, entering a new upward cycle due to the continuous support for innovative drugs and the recovery of overseas demand [7][24] - The CXO sector is expected to see a gradual recovery in operating performance, with a recommendation to actively invest in this direction [6][16] - The performance of leading CXO companies is improving, with significant growth in revenue and net profit expected in the first half of 2025 [14][17] Summary by Sections CXO Sector - The CXO industry has shown a recovery trend, with total revenue of 24 core companies reaching approximately 592.2 billion yuan, a year-on-year increase of about 16.6% in the first half of 2025 [14] - Leading CXO companies like WuXi AppTec and WuXi Biologics are experiencing significant improvements in their performance, with net profit growth of 62.7% [14][17] - The demand for ADC and weight-loss industry chains is strong, contributing to the robust growth of companies like WuXi AppTec and WuXi AppTec [17] Life Sciences Upstream - The life sciences upstream sector is witnessing a clear turning point, with most companies showing significant performance improvement [24] - Bioreagent companies are experiencing steady growth in conventional business, while unconventional business impacts are largely cleared [24] - Chemical reagents are maintaining high growth, with companies like Haoyuan Pharmaceutical and Bid Pharma exceeding revenue and net profit expectations [24] Recommended and Benefiting Companies - Recommended companies in the pharmaceutical and biotechnology sector include: Heng Rui Medicine, East China Medicine, Sanofi, and others [8] - In the CXO sector, recommended companies include WuXi AppTec, WuXi Biologics, and others [8] - In the research service sector, recommended companies include Bid Pharma, Baipusai, and others [8]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology industry [7] Core Insights - The report highlights that the pharmaceutical sector is experiencing a rebound, particularly in innovative drugs and their supply chains, with a strong emphasis on the potential for a second wave of innovation over the next 5-10 years [3][4][12] - The report indicates that the recent market adjustments have not altered the fundamental industry logic, and the core theme for innovative drugs is "disruption" [3][4][14] Summary by Sections 1. Industry Performance - The pharmaceutical index increased by 1.40% during the week of September 1-5, underperforming the ChiNext index but outperforming the CSI 300 index [12] - The market has shown a tendency for larger stocks to perform better than smaller ones, with innovative drugs and their supply chains being the main focus [2][3] 2. Recent Review - The report notes a significant rebound in the market after a period of adjustment, with innovative drugs remaining the strongest sector [3][4] - The report emphasizes that the recent adjustments in innovative drug stocks are primarily market-driven and do not reflect changes in industry fundamentals [3][4][14] 3. Future Outlook - The report suggests a continued focus on innovative drugs, particularly overseas large pharmaceuticals and small to mid-cap technology revolutions, with an optimistic outlook for 2025 [4][15] - Key investment themes include innovative drugs, new technologies like brain-computer interfaces and AI in medicine, and internationalization of research instruments and equipment [4][15][16] 4. Strategic Allocation - The report outlines specific companies to focus on within the innovative drug sector, including major players like Innovent Biologics and BeiGene, as well as smaller firms involved in gene therapy and weight loss drugs [16][17] - It also highlights opportunities in new technologies and internationalization, suggesting a diversified approach to investment within the pharmaceutical sector [16][18]

Group 1: Market Overview - The Hong Kong capital market is expected to see a significant recovery in 2025, with IPO financing reaching HKD 132.9 billion in the first eight months, a 50% increase compared to the total for 2024 [1] - The secondary market for Hong Kong stock offerings is performing even stronger, raising HKD 190.5 billion, which is 3.8 times higher than the total for 2024, with an average fundraising size of HKD 1.1 billion per project [1] Group 2: Underwriting Market Characteristics - The underwriting market for Hong Kong stock offerings in 2025 shows a "head concentration and foreign capital leading" characteristic, with six out of the top ten underwriters being foreign investment banks [3] - The top six underwriters have all surpassed HKD 15 billion in underwriting scale, collectively accounting for over 70% of the overall market [3] Group 3: Top Underwriters - Goldman Sachs leads the underwriting market with a scale of HKD 39.5 billion, holding a market share of approximately 21%, and has a strong focus on "head large projects" [5] - CITIC Securities ranks second with HKD 24.8 billion, but its underwriting structure is heavily reliant on a single large project, which limits its overall project diversity [6] - UBS ranks third with HKD 24.1 billion, demonstrating a balanced approach with both large and small projects, contributing to its competitive position [7] Group 4: Performance Discrepancies - CICC, while being the top underwriter for IPOs, has seen a significant drop in its performance in the secondary market, with only HKD 21.3 billion in underwriting scale, indicating a disconnect in core client cooperation [8][9] - Guotai Junan, despite having the highest number of projects at 27, has a low underwriting scale of HKD 9.7 billion, reflecting its inability to secure large projects [10]

Group 1: Market Overview - The Hong Kong capital market is expected to see a significant recovery in 2025, with IPO financing reaching HKD 132.9 billion in the first eight months, a 50% increase compared to the total for 2024 [1] - The secondary market for Hong Kong stock offerings is performing even stronger, raising HKD 190.5 billion, which is 3.8 times higher than the total for 2024, with an average fundraising size of HKD 1.1 billion per project [1] Group 2: Underwriting Market Characteristics - The underwriting market for Hong Kong stock offerings in 2025 shows a "head concentration and foreign capital leading" characteristic, with six out of the top ten underwriters being foreign investment banks [3] - The top six underwriters have all surpassed HKD 15 billion in underwriting scale, collectively accounting for over 70% of the overall market [3] Group 3: Top Underwriters - Goldman Sachs leads the underwriting market with a scale of HKD 39.5 billion, holding approximately 21% market share, and has a strong focus on "head large projects" [5] - CITIC Securities ranks second with HKD 24.8 billion, but its underwriting structure is heavily reliant on a single large project, which limits its overall capability [6] - UBS ranks third with HKD 24.1 billion, demonstrating a balanced approach with both large and small projects, contributing to its competitive position [7] Group 4: Performance Discrepancies - CICC, while being the top underwriter for IPOs, has seen a significant drop in its performance in the secondary market, with only HKD 21.3 billion in underwriting scale [8] - Guotai Junan, despite having the highest number of projects at 27, has a low underwriting scale of HKD 9.7 billion, indicating a lack of large project breakthroughs [10]

Group 1: Market Overview - The Hong Kong capital market is experiencing a significant recovery in 2025, with IPO financing reaching HKD 132.9 billion in the first eight months, a 50% increase compared to the total for 2024, marking a four-year high [1] - The secondary market for Hong Kong stocks is showing even stronger performance, with fundraising reaching HKD 190.5 billion, which is 3.8 times higher than the total for 2024, and an average fundraising size of HKD 1.1 billion per project [1] Group 2: Underwriting Market Characteristics - The underwriting market for Hong Kong stock issuances in 2025 is characterized by a concentration of top players, with foreign investment banks holding six of the top ten spots, including Goldman Sachs, UBS, and Morgan Stanley [2] - The top six underwriters have all surpassed HKD 15 billion in underwriting scale, collectively accounting for over 70% of the overall market [2] Group 3: Top Underwriters - Goldman Sachs leads the underwriting rankings with an underwriting scale of HKD 39.5 billion, holding a market share of approximately 21%, and is known for its focus on "head projects" [4][5] - CITIC Securities ranks second with HKD 24.8 billion in underwriting scale, but its performance is heavily reliant on a single large project, the HKD 43.5 billion issuance from BYD, which accounts for about 60% of its total underwriting [6] - UBS ranks third with HKD 24.1 billion, demonstrating a balanced approach by participating in both large and small projects, which enhances its structural resilience [7] Group 4: Performance Discrepancies - China International Capital Corporation (CICC) is the top underwriter for IPOs but has seen a significant drop in its performance in the secondary market, with only HKD 21.3 billion in underwriting scale, indicating a disconnect in core client cooperation [8][9] - Guotai Junan, despite having the highest number of projects at 27, ranks seventh in terms of underwriting scale at HKD 9.7 billion, primarily due to a lack of participation in large projects [10]

Group 1: Market Overview - The Hong Kong capital market is experiencing a significant recovery in 2025, with IPO financing reaching HKD 132.9 billion in the first eight months, marking a 50% increase compared to the total for 2024, which is the highest in nearly four years [1] - The secondary market for Hong Kong stocks is showing even stronger performance, with fundraising reaching HKD 190.5 billion, which is 3.8 times higher than the total for 2024, and the average fundraising per project is HKD 1.1 billion [1] Group 2: Underwriting Market Characteristics - The underwriting market for Hong Kong stock issuances in 2025 is characterized by a concentration of top players and a leading role of foreign investment banks, with six out of the top ten underwriters being foreign [3] - The top six underwriters have all surpassed HKD 15 billion in underwriting scale, collectively accounting for over 70% of the overall market [3] Group 3: Top Underwriters - Goldman Sachs leads the underwriting rankings with an underwriting scale of HKD 39.5 billion, holding a market share of approximately 21%, and has a strong focus on "top-tier projects" [5] - CITIC Securities ranks second with HKD 24.8 billion in underwriting scale, but its performance is heavily reliant on a single large project, which raises concerns about its ability to diversify its project coverage [6] - UBS ranks third with HKD 24.1 billion, demonstrating a balanced approach by participating in both large and small projects, which enhances its structural resilience [7] Group 4: Performance Discrepancies - China International Capital Corporation (CICC) is the top underwriter for IPOs but has seen a significant drop in its performance in the secondary market, with only HKD 21.3 billion in underwriting scale, indicating a disconnect in core client cooperation [8][9] - Guotai Junan, after its merger, has the highest number of projects at 27 but ranks seventh in underwriting scale at HKD 9.7 billion, highlighting its struggle to secure large projects [9]

Core Viewpoint - The article discusses the quarterly review changes of the FTSE China A50 index announced by FTSE Russell, highlighting the inclusion and exclusion of specific stocks and the implications for investment funds tracking the index [5][6]. Group 1: Index Changes - Four stocks, including BeiGene, NewEase, WuXi AppTec, and Zhongji Xuchuang, will be added to the FTSE China A50 index, while China Nuclear Power, China Unicom, Guodian NARI, and Wanhua Chemical will be removed [5]. - The newly added stocks belong to the innovative drug and CPO sectors, while the removed stocks are from traditional industries such as utilities and telecommunications [5]. - The newly included stocks have shown significant price increases this year, with NewEase and Zhongji Xuchuang rising over 200%, and BeiGene and WuXi AppTec around 90% [5]. Group 2: Market Impact - The estimated size of passive funds tracking the FTSE China A50 index exceeds $10 billion, indicating that changes in constituent stocks can lead to substantial capital flows, potentially in the hundreds of millions to billions [5]. - Investors have raised concerns about the inclusion of stocks perceived as overvalued and whether this adjustment is a strategy for foreign capital to take over high-priced stocks [6]. - The adjustment is based on market capitalization and liquidity criteria, with the review conducted quarterly, using data from the third Friday of February, May, August, and November [6].

致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年9月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 91,150,340 | | | RMB | | 91,150,340 | | 本月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 重新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年9月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 91,150,340 | | | RMB | | 91,150,340 | | 本月底結存 | | | 478,226,490 | RMB | | 1 RMB | | 478,226,490 | | 2. 股份分類 ...